Internal and Emergency Medicine

, Volume 3, Issue 2, pp 179–182 | Cite as

Plasma derived protein C in severe sepsis: report of two cases

  • A. TuttolomondoEmail author
  • A. Pinto
  • D. Di Raimondo
  • P. Fernandez
  • G. Licata
CE - Letter to the Editor

Severe sepsis is defined as sepsis-associated organ dysfunction, (arterial hypoxemia, acute oliguria, coagulation abnormalities, thrombocytopenia, hyperbilirubinemia), hypoperfusion (hyperlactatemia) and arterial hypotension (mean arterial pressure <70 mmHg, or a systolic blood pressure decrease >40 mmHg) [3, 4]. Septic shock [3, 4] is defined as acute circulatory failure induced by sepsis with hypotension despite adequate fluid resuscitation.

A dysfunction of the protein C (PC) pathway is always present in severe sepsis and contributes to the development of coagulopathy and necrosis [12, 13]. This decrease is caused by consumption of protein C during systemic activation of blood coagulation and by reduced hepatic synthesis owing to septic liver dysfunction, but also by degradation of protein C by proteolytic enzymes, such as elastase, released by white blood cells [7].

Numerous studies have demonstrated that decreased circulating levels of protein C in septic patients are associated...


Severe Sepsis Mean Arterial Pressure Teicoplanin Sofa Score Drotrecogin Alfa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Abraham E, Laterre PF, Garg R et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl JMed 353:1332–1341CrossRefGoogle Scholar
  2. 2.
    Bernard GR, Vincent JL, Laterre PF et al (2001) Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRefGoogle Scholar
  3. 3.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJl (1992) Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest 101:1644–1655PubMedCrossRefGoogle Scholar
  4. 4.
    Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM (2004) Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock. Crit Care Med 32:858–873PubMedCrossRefGoogle Scholar
  5. 5.
    Deventer SJ, ten Cate JW (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 73:15–20PubMedGoogle Scholar
  6. 6.
    Ettinghausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W (1999) Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 25:537–541CrossRefGoogle Scholar
  7. 7.
    Esmon CT (2001) Role of coagulation inhibitors in inflammation. Thromb Haemost 86:51–56PubMedGoogle Scholar
  8. 8.
    Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJ, ten Cate JW (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 73:15–20PubMedGoogle Scholar
  9. 9.
    Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101:816–823PubMedCrossRefGoogle Scholar
  10. 10.
    Fourrier F, Leclerc F, Aidan K et al (2003) Combined antithrombin and PC supplementation in meningococcal purpura fulminans: a pharmacokinetic study. Intensive Care Med 29:1081–1087PubMedCrossRefGoogle Scholar
  11. 11.
    Green C, Dinnes J, Takeda AL, Cuthbertson BH (2006) Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Int J Technol Assess Health Care 22:90–100PubMedCrossRefGoogle Scholar
  12. 12.
    Levi M, ten Cate H, van der Poll T, van Deventer SJ (1993) Pathogenesis of dissemnated intravascular coagulation in sepsis. JAMA 270:975–979PubMedCrossRefGoogle Scholar
  13. 13.
    Levi M, van der Poll T, ten Cate H, van Deventer SJ (1997) The cytokine mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 27:3–9PubMedCrossRefGoogle Scholar
  14. 14.
    Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A (1993) Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103:1536–1542PubMedCrossRefGoogle Scholar
  15. 15.
    Macias WL, Nelson DR (2004) Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 32(5 Suppl):S223–S228PubMedCrossRefGoogle Scholar
  16. 16.
    Rintala E, Kauppila M, Seppala OP et al (2000) Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28:2373–2378PubMedCrossRefGoogle Scholar
  17. 17.
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy collaborative group early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedCrossRefGoogle Scholar
  18. 18.
    Vincent JL, Angus DC, Artigas A et al (2003) Effects of drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31:834–840PubMedCrossRefGoogle Scholar
  19. 19.
    Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367PubMedCrossRefGoogle Scholar
  20. 20.
    Wheeler AP, Bernard GR (1999) Treating patients with severe sepsis. N Engl J Med 340:207–214PubMedCrossRefGoogle Scholar
  21. 21.
    White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP (2000) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans–associated meningococcemia. Blood 96:3719–3724PubMedGoogle Scholar

Copyright information

© SIMI 2008

Authors and Affiliations

  • A. Tuttolomondo
    • 1
    Email author
  • A. Pinto
    • 1
  • D. Di Raimondo
    • 1
  • P. Fernandez
    • 1
  • G. Licata
    • 1
  1. 1.Biomedical Department of Internal and Specialist MedicineUniversity of PalermoPalermoItaly

Personalised recommendations